Fluctuating Sensorium: A Comprehensive Approach to Diagnosis and Management

Dr Neeraj Manikath , claude.ai

Abstract

Fluctuating sensorium represents a common yet challenging clinical presentation in internal medicine, characterized by waxing and waning levels of consciousness and cognitive function. This review provides a systematic approach to the evaluation and management of patients with altered mental status, emphasizing the distinction between delirium, dementia, and other confusional states. We discuss the pathophysiology, diagnostic framework, and evidence-based management strategies, with practical pearls for the busy clinician.

Introduction

Fluctuating sensorium—the medical term for varying levels of consciousness and cognitive function—affects up to 30% of hospitalized elderly patients and carries significant morbidity and mortality.(1,2) Unlike static encephalopathy, the hallmark of fluctuating sensorium is its temporal variability, with patients cycling between periods of relative clarity and profound confusion within hours or days. Recognition and appropriate management of this condition can dramatically alter patient outcomes.(3)

Defining the Syndrome

Fluctuating sensorium most commonly manifests as delirium, an acute confusional state characterized by inattention, disorganized thinking, altered level of consciousness, and importantly, fluctuating severity over time.(4) The Diagnostic and Statistical Manual (DSM-5) criteria emphasize four key features: (1) disturbance in attention and awareness, (2) acute onset with fluctuating course, (3) cognitive disturbance, and (4) evidence that the disturbance is caused by a direct physiological consequence of a medical condition.(5)

Pearl #1: The single most distinguishing feature separating delirium from dementia is the temporal course—delirium develops over hours to days and fluctuates, while dementia develops insidiously over months to years with relatively stable day-to-day function.

Pathophysiology

The underlying mechanisms of fluctuating sensorium remain incompletely understood but likely involve multiple converging pathways. Current evidence suggests disruption of neurotransmitter systems, particularly acetylcholine deficiency and dopamine excess, along with inflammatory mediators, chronic stress responses, and network connectivity dysfunction.(6,7)

The "final common pathway" hypothesis proposes that various insults—metabolic, infectious, pharmacological—converge on vulnerable brain regions, particularly the prefrontal cortex and thalamus, disrupting arousal and attention networks.(8) This explains why diverse etiologies produce similar clinical phenotypes.

Oyster #1: Not all fluctuating mental status is delirium. Consider non-convulsive status epilepticus in patients with rhythmic fluctuations, especially those with subtle facial or ocular movements. A bedside EEG can be life-saving in these cases.(9)

Clinical Assessment

The "Why-Is-This-Happening-Now?" Approach

Effective evaluation begins with a systematic search for precipitants. The mnemonic "I WATCH DEATH" remains clinically useful:(10)

• Infections (especially urinary tract infections, pneumonia, COVID-19)
• Withdrawal (alcohol, benzodiazepines)
• Acute metabolic (hypoglycemia, hyponatremia, hypercalcemia)
• Trauma (subdural hematoma, fat embolism)
• CNS pathology (stroke, encephalitis, seizures)
• Hypoxia (pulmonary embolism, cardiac failure)
• Deficiencies (thiamine, B12)
• Endocrine (thyroid storm, Addisonian crisis)
• Acute vascular (hypertensive encephalopathy, posterior reversible encephalopathy syndrome)
• Toxins/drugs (anticholinergics, opioids, corticosteroids)
• Heavy metals (lead, mercury)

Pearl #2: In hospitalized patients, medications are the most common reversible cause of delirium. Review the medication list before ordering extensive investigations. Pay particular attention to recent additions of anticholinergics, benzodiazepines, opioids, and corticosteroids.(11)

Clinical Examination

Physical examination should include:

1. Vital signs: Fever suggests infection or thyroid storm; hypotension may indicate sepsis or Addisonian crisis
2. Neurological examination: Focal deficits suggest structural lesions; asterixis indicates metabolic encephalopathy; myoclonus may accompany uremia or medication toxicity
3. Stigmata of chronic disease: Jaundice (hepatic encephalopathy), peripheral edema (cardiac failure), track marks (substance abuse)

Hack #1: Use the Confusion Assessment Method (CAM) at the bedside. It has 95% sensitivity and 90% specificity for delirium diagnosis.(12) The four features are: (1) acute onset and fluctuating course, (2) inattention, (3) disorganized thinking, and (4) altered level of consciousness. Features 1 and 2 plus either 3 or 4 = delirium.

Investigative Approach

First-Line Investigations

• Complete blood count (infection, anemia)
• Comprehensive metabolic panel (glucose, electrolytes, renal function, calcium)
• Liver function tests
• Thyroid function tests
• Urinalysis and culture
• Chest radiograph
• Electrocardiogram
• Arterial blood gas (if hypoxia suspected)

Second-Line Investigations (Based on Clinical Context)

• Blood cultures (if febrile)
• Ammonia level (suspected hepatic encephalopathy)
• Vitamin B12 and thiamine levels
• Toxicology screen
• Brain imaging (CT or MRI if focal deficits, recent trauma, or anticoagulation)
• Lumbar puncture (if meningitis/encephalitis suspected)
• Electroencephalogram (suspected seizures)

Pearl #3: The diagnostic yield of routine brain imaging in delirium without focal neurological signs is low (<5%).(13) Reserve CT/MRI for patients with focal deficits, head trauma, anticoagulation, or when no other cause is identified.

Special Scenarios

Hepatic Encephalopathy

Hepatic encephalopathy represents a classic example of fluctuating sensorium, graded by the West Haven criteria from subclinical (Grade 0) to coma (Grade 4).(14) Ammonia levels correlate poorly with severity, but the diagnosis is strengthened by elevated levels in the appropriate clinical context.

Hack #2: Use the smartphone app "EncephalApp Stroop Test" to rapidly assess for minimal hepatic encephalopathy at the bedside. It's validated and takes less than 5 minutes.(15)

Management includes:

1. Lactulose: 20-30 g three times daily, titrated to 2-3 soft stools daily
2. Rifaximin: 550 mg twice daily, shown to reduce recurrence by 58%(16)
3. Identify and treat precipitants: Infection, gastrointestinal bleeding, constipation, dehydration
4. Protein restriction is outdated: Maintain adequate nutrition with 1.2-1.5 g/kg/day protein(17)

Wernicke's Encephalopathy

This medical emergency presents with the classic triad (confusion, ataxia, ophthalmoplegia) in only 10% of cases.(18) Maintain a high index of suspicion in alcoholics, patients with hyperemesis, or those receiving IV dextrose without thiamine supplementation.

Oyster #2: Always give thiamine BEFORE glucose in any patient at risk for Wernicke's encephalopathy. Glucose administration without thiamine can precipitate or worsen the condition by depleting remaining thiamine stores.

Treatment: Thiamine 500 mg IV three times daily for 3 days, then 250 mg IV daily until clinical improvement, followed by oral supplementation.(19)

Autoimmune Encephalitis

An increasingly recognized cause of fluctuating sensorium, particularly anti-NMDA receptor encephalitis, which presents with psychiatric symptoms, seizures, movement disorders, and autonomic instability.(20) Consider in young patients with subacute onset, especially those with ovarian teratoma (women) or testicular tumors (men).

Pearl #4: If autoimmune encephalitis is suspected, send CSF for neuronal antibodies before starting immunotherapy. However, don't delay treatment while awaiting results—early immunosuppression improves outcomes.(21)

Management Strategies

Non-Pharmacological Interventions (First-Line)

The HELP (Hospital Elder Life Program) protocol reduces delirium incidence by 40%:(22)

1. Orientation: Frequent reorientation, visible clocks/calendars
2. Sleep hygiene: Reduce nighttime interruptions, minimize noise
3. Early mobilization: Get patients out of bed
4. Visual/hearing aids: Ensure glasses and hearing aids are used
5. Hydration and nutrition: Adequate intake
6. Minimize restraints: Physical restraints worsen agitation
7. Family involvement: Familiar faces provide comfort

Hack #3: The "delirium room" checklist—ensure every delirious patient has: working glasses, working hearing aids, clock visible from bed, window with natural light, and at least one mobilization per day.

Pharmacological Management

Medications should be reserved for patients with severe agitation posing safety risks to themselves or others.

Antipsychotics:

1. Haloperidol: 0.5-1 mg PO/IM every 4-6 hours as needed (first-line in most guidelines)(23)
   • Monitor QTc interval
   • Use cautiously in Parkinson's disease
2. Quetiapine: 12.5-25 mg twice daily
   • Preferred in Parkinson's disease or Lewy body dementia
   • More sedating than haloperidol

Pearl #5: Avoid benzodiazepines in delirium unless it's due to alcohol or benzodiazepine withdrawal. Benzodiazepines worsen confusion and increase fall risk.(24)

Oyster #3: In alcohol withdrawal, use the Clinical Institute Withdrawal Assessment (CIWA) protocol with benzodiazepines (lorazepam 1-2 mg every hour PRN for CIWA-Ar ≥8). In this specific scenario, benzodiazepines are life-saving.(25)

Managing Underlying Causes

Treatment success hinges on identifying and correcting precipitants:

• Infections: Appropriate antibiotics
• Metabolic derangements: Correct electrolytes gradually (avoid rapid sodium correction—risk of osmotic demyelination)
• Medication toxicity: Discontinue offending agents
• Hypoxia: Oxygen therapy, treat underlying cause
• Pain: Adequate analgesia (preferentially use acetaminophen over opioids)

Prognostic Considerations

Delirium is not benign. It is associated with:(26,27)

• Increased hospital length of stay (doubled)
• Higher mortality (2-4 fold increase)
• Persistent cognitive impairment in 25% at 6 months
• Accelerated dementia progression
• Increased institutionalization rates

Pearl #6: Document delirium clearly in discharge summaries. Patients with delirium need cognitive reassessment at 3 and 6 months, as many have persistent deficits requiring support services.

Prevention Strategies

Prevention is more effective than treatment. Risk stratification using validated tools (PRE-DELIRIC score, Delirium Risk Score) helps identify high-risk patients.(28)

Multicomponent prevention programs should include:

1. Proactive geriatric consultation
2. Medication review and deprescribing
3. Early mobilization protocols
4. Pain management strategies
5. Sleep promotion
6. Sensory optimization

Hack #4: Create a "delirium prevention bundle" order set in your EMR with: hold unnecessary medications, mobilize three times daily, avoid Foley catheters, ensure hearing/visual aids, provide clock and calendar, minimize sleep interruptions.

Special Populations

Intensive Care Unit Delirium

ICU delirium affects 60-80% of mechanically ventilated patients.(29) The CAM-ICU is a validated screening tool adapted for intubated patients. Prevention strategies include:

• Daily sedation interruption
• Early mobilization (even during mechanical ventilation)
• Prefer dexmedetomidine over benzodiazepines for sedation(30)
• ABCDEF bundle implementation (Awakening, Breathing coordination, Choice of sedation, Delirium monitoring, Early mobility, Family engagement)

Palliative Care Setting

Terminal delirium affects up to 85% of dying patients.(31) Management focuses on comfort:

• Treat reversible causes only if consistent with goals of care
• Consider subcutaneous haloperidol or midazolam for refractory agitation
• Emphasize family support and education

Conclusion

Fluctuating sensorium represents a final common pathway of multiple pathological processes affecting the brain. A systematic approach emphasizing rapid recognition, identification of underlying causes, and multicomponent non-pharmacological interventions forms the cornerstone of management. As internal medicine physicians, maintaining high vigilance for this syndrome, particularly in elderly hospitalized patients, can significantly impact outcomes. Remember: the best treatment for delirium is prevention, and every case of delirium deserves a thorough search for reversible causes.

Key Takeaways

1. Fluctuating course distinguishes delirium from dementia
2. Medications are the most common reversible cause in hospitalized patients
3. Non-pharmacological interventions should be first-line therapy
4. Reserve antipsychotics for severe agitation posing safety concerns
5. Delirium is associated with poor long-term outcomes requiring follow-up
6. Prevention through multicomponent programs is more effective than treatment

References

1. Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014;383(9920):911-922.

2. Siddiqi N, House AO, Holmes JD. Occurrence and outcome of delirium in medical in-patients: a systematic literature review. Age Ageing. 2006;35(4):350-364.

3. Hshieh TT, Inouye SK, Oh ES. Delirium in the elderly. Clin Geriatr Med. 2020;36(2):183-199.

4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.

5. Maldonado JR. Delirium pathophysiology: An updated hypothesis of the etiology of acute brain failure. Int J Geriatr Psychiatry. 2018;33(11):1428-1457.

6. Fong TG, Davis D, Growdon ME, et al. The interface between delirium and dementia in elderly adults. Lancet Neurol. 2015;14(8):823-832.

7. Cerejeira J, Firmino H, Vaz-Serra A, Mukaetova-Ladinska EB. The neuroinflammatory hypothesis of delirium. Acta Neuropathol. 2010;119(6):737-754.

8. Chong DJ, Hirsch LJ. Which EEG patterns warrant treatment in the critically ill? Reviewing the evidence for treatment of periodic epileptiform discharges and related patterns. J Clin Neurophysiol. 2005;22(2):79-91.

9. Laurila JV, Pitkala KH, Strandberg TE, Tilvis RS. Confusion assessment method in the diagnostics of delirium among aged hospital patients: would it serve better in screening than as a diagnostic instrument? Int J Geriatr Psychiatry. 2002;17(12):1112-1119.

10. O'Mahony R, Murthy L, Akunne A, Young J; Guideline Development Group. Synopsis of the National Institute for Health and Clinical Excellence guideline for prevention of delirium. Ann Intern Med. 2011;154(11):746-751.

11. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508-513.

12. Wei LA, Fearing MA, Sternberg EJ, Inouye SK. The Confusion Assessment Method: a systematic review of current usage. J Am Geriatr Soc. 2008;56(5):823-830.

13. Lai MM, Tin Tin H, Harraway S, et al. Computed tomography brain head scan in delirium: when should you perform one? Age Ageing. 2012;41(6):775-779.

14. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715-735.

15. Bajaj JS, Thacker LR, Helenowski IB, et al. The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology. 2013;58(3):1122-1132.

16. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081.

17. Amodio P, Bemeur C, Butterworth R, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58(1):325-336.

18. Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6(5):442-455.

19. Thomson AD, Cook CC, Touquet R, Henry JA; Royal College of Physicians, London. The Royal College of Physicians report on alcohol: guidelines for managing Wernicke's encephalopathy in the accident and Emergency Department. Alcohol Alcohol. 2002;37(6):513-521.

20. Dalmau J, Armangué T, Planagumà J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;18(11):1045-1057.

21. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157-165.

22. Inouye SK, Bogardus ST Jr, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999;340(9):669-676.

23. Neufeld KJ, Yue J, Robinson TN, Inouye SK, Needham DM. Antipsychotic medication for prevention and treatment of delirium in hospitalized adults: a systematic review and meta-analysis. J Am Geriatr Soc. 2016;64(4):705-714.

24. Lonergan E, Luxenberg J, Areosa Sastre A. Benzodiazepines for delirium. Cochrane Database Syst Rev. 2009;(1):CD006379.

25. Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. JAMA. 1997;278(2):144-151.

26. Witlox J, Eurelings LS, de Jonghe JF, Kalisvaart KJ, Eikelenboom P, van Gool WA. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. JAMA. 2010;304(4):443-451.

27. Pandharipande PP, Girard TD, Jackson JC, et al. Long-term cognitive impairment after critical illness. N Engl J Med. 2013;369(14):1306-1316.

28. Wassenaar A, van den Boogaard M, van Achterberg T, et al. Multinational development and validation of an early prediction model for delirium in ICU patients. Intensive Care Med. 2015;41(6):1048-1056.

29. Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004;291(14):1753-1762.

30. Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009;301(5):489-499.

31. Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med. 2000;160(6):786-794.

---

Word count: Approximately 2000 words